UNLIMITED TURBO SHORT - NOVO-NORDISK B | Market Closed - Boerse Frankfurt Warrants 15:21:18 28/06/2024 BST | ||
| 0.5 EUR | -16.67% |
|
| Current month | -68.35% | ||
| 1 month | -71.91% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 0.5 | -16.67% |
| 27/06/24 | 0.6 | +27.66% |
| 26/06/24 | 0.47 | +23.68% |
| 25/06/24 | 0.38 | -51.28% |
| 24/06/24 | 0.78 | -1.27% |
Real-time Boerse Frankfurt Warrants
Last update June 28, 2024 at 03:21 pm
More quotesStatic data
| Product type | Knock-Out sin Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| WKN | PC4GQN |
| ISIN | DE000PC4GQN6 |
| Date issued | 02/02/2024 |
| Strike | 1,043 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.58 € |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.71 € |
|---|---|
| Lowest since issue | 0.32 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
- Stock Market
- Certificates
- Certificat
